The US Court of Appeals has dismissed appeals from Johnson & Johnson and Bristol Myers Squibb regarding the government’s Medicare drug price negotiation program. This ruling reinforces the legal framework supporting the Biden administration’s efforts to negotiate lower drug prices under Medicare, a significant policy shift aimed at reducing healthcare costs for millions of Americans.
The implications of this decision are profound for pharmaceutical companies, as it sets a precedent that may deter future legal challenges against price negotiations. With the administration poised to expand its negotiation powers, companies in the pharma sector must prepare for an evolving landscape where pricing strategies will be increasingly scrutinized. This ruling not only affects the financial outlook of these companies but also signals to investors and stakeholders the potential for regulatory pressures that could reshape market dynamics.
Sponsored: Regulatory hurdles often delay launches and put supply chains at risk. API & FDF Intelligence shows who holds DMFs and CEPs, where dossiers are registered, and which companies have inspection findings. At the same time, users can view API and FDF price benchmarks, assess risk profiles for specific manufacturers, and identify alternative suppliers. All company details — emails, phone numbers, addresses — are openly listed. For an individual user, full access is available for $42/month, without the need to go through intermediaries. Learn more.
